グルココルチコイド療法とフィブロガミン® (浄化凝固因子XIII濃縮物) の投与による重度の下痢と低アルブミニアとして表されるIgA血管炎の疑いの緩和:症例報告
Takashi Aikawa1, Takashi Negishi1, Tomohiro Iida1
1Internal Medicine, Kiryu Kosei General Hospital, Kiryu, JPN.
Cureus
|September 5, 2025
まとめ
このケーススタディは,62歳の女性の免疫グロブリンA (IgA) 血管炎関連腸内炎を調査しています. グルココルチコイドとファクターXIII濃縮剤による治療は,重度の胃腸症状を改善しました.
科学分野:
- 胃腸内科
- 免疫学
- 内科 医学
背景:
- 免疫グロブリンA (IgA) 血管炎は,ヘノク・シュンラインの紫外線として知られ,胃腸に影響を及ぼし,腸内炎を引き起こす可能性があります.
- IgA血管炎の胃腸内症状は,腹痛から重度の下痢や出血まで様々です.
- 診断は困難であり,特に非典型的な表現や特定の組織学的発見がない場合です.
研究 の 目的:
- 重度の下痢を伴うIgA血管炎に関連する腸内炎の疑いのある症例を報告する.
- この患者の診断の課題と 治療方法について話し合います
- IgA血管炎による重度の腸内炎の管理におけるグルココルチコイドとXIII因子濃度の潜在的な役割を強調する.
主な方法:
- 62歳の女性で 胃腸の症状が重かった
- エソファゴガストロドオデノスコピー,全腸内視鏡検査,生検を含む診断検査
- グルココルチコイドと精製された凝固因子XIII濃縮物 (フィブロガミン®) の治療介入
主要な成果:
- 患者は重度の下痢 (30回/日),低アルブミン血症,低ナトリウム血症を発症した.
- 内視鏡検査では 十二指腸,末端の帯,大腸に 拡散した侵食が確認された.
- バイオプシでは周周粘膜のIgA陽性リンパ球が示されましたが,毛細血管壁のIgA沈殿や他の特徴的な発見はありませんでした.
- 患者は1ヶ月半の治療後に下痢の臨床改善を示した.
結論:
- 重度の胃腸症候群の患者および生検の結果が示唆されるが,決定的ではない患者では,耐性IgA血管炎に関連した腸内炎の可能性がある.
- グルココルチコイドとファクターXIII濃縮剤を併用した治療は,このような症例の管理に有益である可能性があります.
- IgA血管炎に関連した腸内炎の正確な病理学と最適な治療戦略を明らかにするために,さらなる研究が必要である.
関連する概念動画
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
200
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
200
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
Inflammatory Bowel Disease IV: Pharmacological Management
177
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
177
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
407
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
407


